A Phase 2 interventional study of Zemplar and Placebo in Chronic Kidney Disease, sponsored by Erling Bjerregaard Pedersen. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-25.
Sponsored by Erling Bjerregaard Pedersen · Phase 2, Interventional, and Treatment
Recently it has been documented that vitamin D has important functions in the human body that are unrelated to its primary effects in calcium homeostasis and bone mineralization. In clinical studies, paricalcitol - a low-calcemic vitamin D analogue - has been shown to decrease proteinuria, a marker of disease progression and cardiovascular risk in patients with chronic kidney disease (CKD). The purpose of this study is to investigate the effect of a paricalcitol on renal and cardiovascular variables in patients with moderate to severe CKD.
3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.
This study's enrollment of 30 is below the median of 70 across 2,640 interventional studies indexed under Kidney Diseases.
Browse Kidney Diseases studies →Erling Bjerregaard Pedersen is the lead sponsor of 16 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Zemplar
Drug: Placebo
2 capsules of 1 microgram daily
2 capsules daily
plasma renin concentration
Time frame: 6 weeks
Urinary albumin excretion
Time frame: 6 weeks
GFR
Time frame: 6 weeks
Fractional excretion of sodium
Time frame: 6 weeks
Urinary excretion of aquaporin-2
Time frame: 6 weeks
Urinary excretion of ENaC-beta
Time frame: 6 weeks
Urinary excretion of NCC
Time frame: 6 weeks
Plasma concentration of aldosterone
Time frame: 6 weeks
Plasma concentration of angiotensin-II
Time frame: 6 weeks
Plasma concentration of ADH
Time frame: 6 weeks
Plasma concentration of atrial natriuretic peptide
Time frame: 6 weeks
Plasma concentration of brain natriuretic peptide
Time frame: 6 weeks
Plasma concentration of endothelin
Time frame: 6 weeks
24-hr ambulatory blood pressure
Time frame: 6 weeks
Central blood pressure
Time frame: 6 weeks
Pulse wave velocity
Time frame: 6 weeks
augmentation index
Time frame: 6 weeks
Plasma concentration of ionized calcium
Time frame: 6 weeks
Plasma concentration of phosphate
Time frame: 6 weeks
Plasma concentration of alkaline phosphatase
Time frame: 6 weeks
Plasma concentration of Parathyroid hormon
Time frame: 6 weeks
Plasma concentration of 25-hydroxy-vitamin D
Time frame: 6 weeks
Plasma concentration of ultrasensitive CRP
Time frame: 6 weeks
Plasma concentration of TNF-alpha
Time frame: 6 weeks
Plasma concentration of TGF-beta
Time frame: 6 weeks
Urinary excretion of calcium
Time frame: 6 weeks
Plasma concentration of ADMA
Time frame: 6 weeks
This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Erling Bjerregaard Pedersen